Pharmacogenetics: From Bench to Byte— An Update of Guidelines

2011999 citationsReview

Authors

Jesse J. Swen · Leiden University Medical Center

Marga Nijenhuis · Royal Dutch Pharmacists Association

Anthonius de Boer · Utrecht University

L Grandia · Royal Dutch Pharmacists Association

Anke H. Maitland‐van der Zee · Utrecht University

Johannes Mulder · Utrecht University

Gerard A. Rongen

Abstract

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

Topics & Keywords

Pharmacogenetics and Drug Metabolism Biochemical and Molecular Research Pharmaceutical studies and practices

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Clinical Pharmacology & Therapeutics

Volume 89, Issue 5, pp. 662-673

DOI: 10.1038/clpt.2011.34

Field-Weighted Citation Impact: 78.64